Risk Stratification and MRD-driven Maintenance for MM After ASCT

This study evaluates the maintenance strategy based on risk stratification and MRD status after stem cell transplantation. This is a single-arm, multicenter, prospective study. Participants who are R2-ISS 1,2 and MRD negative receive the single drug lenalidomide maintenance. In other circumstances, for example, patients who are R2-ISS 3 or 4 will receive daratumumab combined with lenalidomide regardless of MRD status, while patients with MRD positivity will also receive daratumumab plus lenalidomide maintenance.

Trial Details

NCT ID
NCT06697483
Phase
NA
Sponsor
Peking University People's Hospital
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Daratumumab
  • Lenalidomide
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Harbin, Heilongjiang, China|45.75,126.65

Key Eligibility Criteria

  • Newly diagnosed multiple myeloma with a history of a minimum of 4 cycles of induction therapy, have received high-dose therapy (HDT) and autologous…
  • Must have a partial response (PR) or better response before maintenance.
  • Must have an Eastern Cooperative Oncology Group performance status score of 0, 1, or 2.
  • This study allows for post-ASCT consolidation therapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →